ARGENICA THERAPEUTICS LIMITED - Announcements

0.72%

70.0¢

Market Cap $91.20M

Healthcare Biotechnology

Argenica Therapeutics Limited is an Australia-based biotechnology company, developing... Argenica Therapeutics Limited is an Australia-based biotechnology company, developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischemic encephalopathy (HIE). The Company has completed a Phase I clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. It has completed dosing in a Phase II clinical trial in ischaemic stroke patients and continues to generate preclinical data in other neurological conditions, including in TBI and HIE.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

AGN	Bioshares Biotech Summit Presentation		08/08/25	2.27MB	Share
AGN	Argenica Appoints Vice President of Regulatory Affairs		06/08/25	197.48KB	Share
AGN	Ceasing to be a substantial holder from IFL		23/07/25	37.06KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/07/25	415.05KB	Share
AGN	Cleansing Notice		09/07/25	178.41KB	Share
AGN	Application for quotation of securities - AGN		09/07/25	16.34KB	Share
AGN	Notification of cessation of securities - AGN		09/07/25	12.83KB	Share
AGN	Application for quotation of securities - AGN		09/07/25	15.75KB	Share
AGN	Argenica Awarded Federal Government Funding	PRICE SENSITIVE	20/06/25	269.41KB	Share
AGN	Argenica to Progress Clinical Development in TBI	PRICE SENSITIVE	18/06/25	454.88KB	Share
AGN	Update on Investigational New Drug Application	PRICE SENSITIVE	10/06/25	208.63KB	Share
AGN	Change of Director's Interest Notice		03/06/25	238.8KB	Share
AGN	Notification of cessation of securities - AGN		03/06/25	12.86KB	Share
AGN	Notification regarding unquoted securities - AGN		03/06/25	17.7KB	Share
AGN	Investor Webinar		23/05/25	193.88KB	Share
AGN	New US Patent for Surgical Stroke	PRICE SENSITIVE	22/05/25	197.4KB	Share
AGN	Investor Presentation		19/05/25	2.44MB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	401.24KB	Share
AGN	Last Patient Dosed in Phase 2 Stroke Trial	PRICE SENSITIVE	11/04/25	263.75KB	Share
AGN	Notification of cessation of securities - AGN		01/04/25	12.76KB	Share
AGN	Change of Share Registry Details		21/03/25	172.43KB	Share
AGN	Investor Presentation		12/03/25	2.34MB	Share
AGN	Final Director's Interest Notice		03/03/25	284.27KB	Share
AGN	Non-Executive Director Resignation		03/03/25	187.11KB	Share
AGN	Half Yearly Report and Accounts	PRICE SENSITIVE	11/02/25	622.94KB	Share
AGN	Updated - Main TBI Injury Study Annoucement	PRICE SENSITIVE	04/02/25	479.14KB	Share
AGN	ARG-007 Shows Significant Neuroprotection in Main TBI Study	PRICE SENSITIVE	04/02/25	468.54KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/25	441.97KB	Share
AGN	Positive DSMB Safety Outcome & Phase 2 Trial Progress Update	PRICE SENSITIVE	30/01/25	305.41KB	Share
AGN	Phase 2 Stroke Clinical Trial Update	PRICE SENSITIVE	10/12/24	287.63KB	Share
AGN	Initial Director's Interest Notice		02/12/24	203.53KB	Share
AGN	Non-Executive Director Appointment		02/12/24	200.63KB	Share
AGN	$2.76m R&D Tax Incentive Cash Rebate Received for FY24	PRICE SENSITIVE	21/11/24	208.65KB	Share
AGN	Final Director's Interest Notice		13/11/24	228.49KB	Share
AGN	AGM Chair's Address & MD Presentation		13/11/24	3.83MB	Share
AGN	Results of Annual General Meeting		13/11/24	248.62KB	Share
AGN	Positive DSMB Safety Outcome & Phase 2 Trial Progress Update	PRICE SENSITIVE	01/11/24	306.15KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report - updated	PRICE SENSITIVE	31/10/24	384.62KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	377.84KB	Share
AGN	FDA Grants ODD & RPDD for Second Drug in Treatment of HIE	PRICE SENSITIVE	30/10/24	281.27KB	Share
AGN	Investor Presentation		29/10/24	2.77MB	Share
AGN	Non-Executive Director Retirement		24/10/24	180.82KB	Share
AGN	Notice of Annual General Meeting/Proxy Form		11/10/24	615.42KB	Share
AGN	Argenica Appoints VP of Product Development		07/10/24	197.81KB	Share
AGN	Positive Results in Key IND Enabling Studies	PRICE SENSITIVE	25/09/24	379.39KB	Share
AGN	Application for quotation of securities - AGN		24/09/24	15.59KB	Share
AGN	Initial Director's Interest Notice x2		17/09/24	286.87KB	Share
AGN	New Appointments to the Board of Directors		17/09/24	187.49KB	Share
AGN	Date of AGM & Closing Date For Director Nominations		17/09/24	177.77KB	Share
AGN	Positive DSMB Safety Outcome & Phase 2 Trial Progress Update	PRICE SENSITIVE	06/09/24	946.1KB	Share
AGN	Appendix 4G & Corporate Governance Statement		28/08/24	512.24KB	Share
AGN	Appendix 4E & Annual Report to 30 June 2024	PRICE SENSITIVE	28/08/24	1.25MB	Share
AGN	Change of Director's Interest Notice		14/08/24	264.06KB	Share
AGN	Notification regarding unquoted securities - AGN		14/08/24	19.26KB	Share
AGN	Results of Meeting		14/08/24	240.66KB	Share
AGN	Change of Director's Interest Notice x3		08/08/24	320.5KB	Share
AGN	Cleansing Notice		08/08/24	228.46KB	Share
AGN	Notification of cessation of securities - AGN		08/08/24	12.9KB	Share
AGN	Application for quotation of securities - AGN		08/08/24	19.02KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	397.6KB	Share
AGN	Phase 2 Stroke Clinical Trial Update	PRICE SENSITIVE	24/07/24	261.01KB	Share
AGN	Investor Webinar Presentation		22/07/24	205.72KB	Share
AGN	Investor Presentation		15/07/24	2.47MB	Share
AGN	Notice of General Meeting/Proxy Form		12/07/24	655.72KB	Share
AGN	Notice of initial substantial holder from IFL		09/07/24	142.2KB	Share
AGN	Cleansing Notice		14/06/24	178.18KB	Share
AGN	Notification of cessation of securities - AGN		14/06/24	12.9KB	Share
AGN	Application for quotation of securities - AGN		14/06/24	15.79KB	Share
AGN	Notification of cessation of securities - AGN		12/06/24	12.8KB	Share
AGN	Final Director's Interest Notice		05/06/24	252.38KB	Share
AGN	Non-Executive Director Resignation		05/06/24	181.03KB	Share
AGN	Change of Director's Interest Notice		05/06/24	267.89KB	Share
AGN	Cleansing Notice		05/06/24	178.16KB	Share
AGN	Notification of cessation of securities - AGN		05/06/24	12.93KB	Share
AGN	Application for quotation of securities - AGN		05/06/24	16.27KB	Share
AGN	ARG-007 Reduces Effects of TBI in Preclinical Study	PRICE SENSITIVE	15/05/24	332.73KB	Share
AGN	DSMB Confirms Safety of First Patients Dosed	PRICE SENSITIVE	29/04/24	263.85KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/04/24	375.6KB	Share
AGN	Cleansing Notice		22/04/24	178.19KB	Share
AGN	Application for quotation of securities - AGN		22/04/24	15.55KB	Share
AGN	Proposed issue of securities - AGN		12/04/24	16.9KB	Share
AGN	Proposed issue of securities - AGN		12/04/24	15.74KB	Share
AGN	Argenica Successfully Completes $12.0m Placement	PRICE SENSITIVE	12/04/24	224.26KB	Share
AGN	Trading Halt	PRICE SENSITIVE	10/04/24	298.63KB	Share
AGN	Patient Dosing Milestone Achieved in Phase 2 Stroke Trial	PRICE SENSITIVE	10/04/24	275.78KB	Share
AGN	First Patient Dosed in Phase 2 Stroke Trial of ARG-007	PRICE SENSITIVE	28/03/24	289.42KB	Share
AGN	FDA Grants Rare Pediatric Disease Designation For HIE	PRICE SENSITIVE	25/03/24	203.44KB	Share
AGN	Application for quotation of securities - AGN		07/03/24	15.58KB	Share
AGN	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/24	706.71KB	Share
AGN	Application for quotation of securities - AGN		16/02/24	15.58KB	Share
AGN	Phase 2 Manufacturing Completed & Trial Update	PRICE SENSITIVE	12/02/24	252.98KB	Share
AGN	Cleansing Notice		02/02/24	190.16KB	Share
AGN	Application for quotation of securities - AGN		02/02/24	24.9KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	427.2KB	Share
AGN	Phase 2 Stroke Clinical Trial Update	PRICE SENSITIVE	14/12/23	275.23KB	Share
AGN	AGM Presentation		01/12/23	3.16MB	Share
AGN	Initial Director's Interest Notice		01/12/23	263.51KB	Share
AGN	Final Director's Interest Notice		01/12/23	253.78KB	Share
AGN	Amended Constitution		01/12/23	599.05KB	Share
AGN	Results of Annual General Meeting		01/12/23	244.69KB	Share

AGN Bioshares Biotech Summit Presentation
08/08/25		2.27MB	Share
AGN Argenica Appoints Vice President of Regulatory Affairs
06/08/25		197.48KB	Share
AGN Ceasing to be a substantial holder from IFL
23/07/25		37.06KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
23/07/25	PRICE SENSITIVE	415.05KB	Share
AGN Cleansing Notice
09/07/25		178.41KB	Share
AGN Application for quotation of securities - AGN
09/07/25		16.34KB	Share
AGN Notification of cessation of securities - AGN
09/07/25		12.83KB	Share
AGN Application for quotation of securities - AGN
09/07/25		15.75KB	Share
AGN Argenica Awarded Federal Government Funding
20/06/25	PRICE SENSITIVE	269.41KB	Share
AGN Argenica to Progress Clinical Development in TBI
18/06/25	PRICE SENSITIVE	454.88KB	Share
AGN Update on Investigational New Drug Application
10/06/25	PRICE SENSITIVE	208.63KB	Share
AGN Change of Director's Interest Notice
03/06/25		238.8KB	Share
AGN Notification of cessation of securities - AGN
03/06/25		12.86KB	Share
AGN Notification regarding unquoted securities - AGN
03/06/25		17.7KB	Share
AGN Investor Webinar
23/05/25		193.88KB	Share
AGN New US Patent for Surgical Stroke
22/05/25	PRICE SENSITIVE	197.4KB	Share
AGN Investor Presentation
19/05/25		2.44MB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	401.24KB	Share
AGN Last Patient Dosed in Phase 2 Stroke Trial
11/04/25	PRICE SENSITIVE	263.75KB	Share
AGN Notification of cessation of securities - AGN
01/04/25		12.76KB	Share
AGN Change of Share Registry Details
21/03/25		172.43KB	Share
AGN Investor Presentation
12/03/25		2.34MB	Share
AGN Final Director's Interest Notice
03/03/25		284.27KB	Share
AGN Non-Executive Director Resignation
03/03/25		187.11KB	Share
AGN Half Yearly Report and Accounts
11/02/25	PRICE SENSITIVE	622.94KB	Share
AGN Updated - Main TBI Injury Study Annoucement
04/02/25	PRICE SENSITIVE	479.14KB	Share
AGN ARG-007 Shows Significant Neuroprotection in Main TBI Study
04/02/25	PRICE SENSITIVE	468.54KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
30/01/25	PRICE SENSITIVE	441.97KB	Share
AGN Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
30/01/25	PRICE SENSITIVE	305.41KB	Share
AGN Phase 2 Stroke Clinical Trial Update
10/12/24	PRICE SENSITIVE	287.63KB	Share
AGN Initial Director's Interest Notice
02/12/24		203.53KB	Share
AGN Non-Executive Director Appointment
02/12/24		200.63KB	Share
AGN $2.76m R&D Tax Incentive Cash Rebate Received for FY24
21/11/24	PRICE SENSITIVE	208.65KB	Share
AGN Final Director's Interest Notice
13/11/24		228.49KB	Share
AGN AGM Chair's Address & MD Presentation
13/11/24		3.83MB	Share
AGN Results of Annual General Meeting
13/11/24		248.62KB	Share
AGN Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
01/11/24	PRICE SENSITIVE	306.15KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report - updated
31/10/24	PRICE SENSITIVE	384.62KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	377.84KB	Share
AGN FDA Grants ODD & RPDD for Second Drug in Treatment of HIE
30/10/24	PRICE SENSITIVE	281.27KB	Share
AGN Investor Presentation
29/10/24		2.77MB	Share
AGN Non-Executive Director Retirement
24/10/24		180.82KB	Share
AGN Notice of Annual General Meeting/Proxy Form
11/10/24		615.42KB	Share
AGN Argenica Appoints VP of Product Development
07/10/24		197.81KB	Share
AGN Positive Results in Key IND Enabling Studies
25/09/24	PRICE SENSITIVE	379.39KB	Share
AGN Application for quotation of securities - AGN
24/09/24		15.59KB	Share
AGN Initial Director's Interest Notice x2
17/09/24		286.87KB	Share
AGN New Appointments to the Board of Directors
17/09/24		187.49KB	Share
AGN Date of AGM & Closing Date For Director Nominations
17/09/24		177.77KB	Share
AGN Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
06/09/24	PRICE SENSITIVE	946.1KB	Share
AGN Appendix 4G & Corporate Governance Statement
28/08/24		512.24KB	Share
AGN Appendix 4E & Annual Report to 30 June 2024
28/08/24	PRICE SENSITIVE	1.25MB	Share
AGN Change of Director's Interest Notice
14/08/24		264.06KB	Share
AGN Notification regarding unquoted securities - AGN
14/08/24		19.26KB	Share
AGN Results of Meeting
14/08/24		240.66KB	Share
AGN Change of Director's Interest Notice x3
08/08/24		320.5KB	Share
AGN Cleansing Notice
08/08/24		228.46KB	Share
AGN Notification of cessation of securities - AGN
08/08/24		12.9KB	Share
AGN Application for quotation of securities - AGN
08/08/24		19.02KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	397.6KB	Share
AGN Phase 2 Stroke Clinical Trial Update
24/07/24	PRICE SENSITIVE	261.01KB	Share
AGN Investor Webinar Presentation
22/07/24		205.72KB	Share
AGN Investor Presentation
15/07/24		2.47MB	Share
AGN Notice of General Meeting/Proxy Form
12/07/24		655.72KB	Share
AGN Notice of initial substantial holder from IFL
09/07/24		142.2KB	Share
AGN Cleansing Notice
14/06/24		178.18KB	Share
AGN Notification of cessation of securities - AGN
14/06/24		12.9KB	Share
AGN Application for quotation of securities - AGN
14/06/24		15.79KB	Share
AGN Notification of cessation of securities - AGN
12/06/24		12.8KB	Share
AGN Final Director's Interest Notice
05/06/24		252.38KB	Share
AGN Non-Executive Director Resignation
05/06/24		181.03KB	Share
AGN Change of Director's Interest Notice
05/06/24		267.89KB	Share
AGN Cleansing Notice
05/06/24		178.16KB	Share
AGN Notification of cessation of securities - AGN
05/06/24		12.93KB	Share
AGN Application for quotation of securities - AGN
05/06/24		16.27KB	Share
AGN ARG-007 Reduces Effects of TBI in Preclinical Study
15/05/24	PRICE SENSITIVE	332.73KB	Share
AGN DSMB Confirms Safety of First Patients Dosed
29/04/24	PRICE SENSITIVE	263.85KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
24/04/24	PRICE SENSITIVE	375.6KB	Share
AGN Cleansing Notice
22/04/24		178.19KB	Share
AGN Application for quotation of securities - AGN
22/04/24		15.55KB	Share
AGN Proposed issue of securities - AGN
12/04/24		16.9KB	Share
AGN Proposed issue of securities - AGN
12/04/24		15.74KB	Share
AGN Argenica Successfully Completes $12.0m Placement
12/04/24	PRICE SENSITIVE	224.26KB	Share
AGN Trading Halt
10/04/24	PRICE SENSITIVE	298.63KB	Share
AGN Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
10/04/24	PRICE SENSITIVE	275.78KB	Share
AGN First Patient Dosed in Phase 2 Stroke Trial of ARG-007
28/03/24	PRICE SENSITIVE	289.42KB	Share
AGN FDA Grants Rare Pediatric Disease Designation For HIE
25/03/24	PRICE SENSITIVE	203.44KB	Share
AGN Application for quotation of securities - AGN
07/03/24		15.58KB	Share
AGN Half Yearly Report and Accounts
28/02/24	PRICE SENSITIVE	706.71KB	Share
AGN Application for quotation of securities - AGN
16/02/24		15.58KB	Share
AGN Phase 2 Manufacturing Completed & Trial Update
12/02/24	PRICE SENSITIVE	252.98KB	Share
AGN Cleansing Notice
02/02/24		190.16KB	Share
AGN Application for quotation of securities - AGN
02/02/24		24.9KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	427.2KB	Share
AGN Phase 2 Stroke Clinical Trial Update
14/12/23	PRICE SENSITIVE	275.23KB	Share
AGN AGM Presentation
01/12/23		3.16MB	Share
AGN Initial Director's Interest Notice
01/12/23		263.51KB	Share
AGN Final Director's Interest Notice
01/12/23		253.78KB	Share
AGN Amended Constitution
01/12/23		599.05KB	Share
AGN Results of Annual General Meeting
01/12/23		244.69KB	Share

REFRESH

1 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 70.0¢		Change 0.005(0.72%)		Mkt cap ! $91.20M

Open	High	Low	Value	Volume
71.0¢	71.0¢	70.0¢	$23.55K	33.33K

Buyers (Bids)

No.	Vol.	Price($)
4	14665	69.5¢

Sellers (Offers)

Price($)	Vol.	No.
71.0¢	4103	1

View Market Depth

No.	Vol.	Price($)
4	14665	0.695
4	54591	0.690
1	55	0.685
1	2000	0.680
1	200	0.675

Price($)	Vol.	No.
0.710	4103	1
0.725	32071	2
0.730	22438	1
0.735	5000	1
0.740	24717	1

Last trade - 10.53am 13/08/2025 (20 minute delay)


Last 70.0¢		Change 0.005 ( 1.10 %)
Open	High	Low	Volume
71.0¢	71.0¢	70.0¢	10423
Last updated 10.53am 13/08/2025 ?

AGN (ASX) Chart

ARGENICA THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available